✦ LIBER ✦

Use of biomarkers as endpoint in trials with subjects with preclinical and prodromal Alzheimer's disease: An ADNI study

✍ Scribed by Bertens, Daniela; Scheltens, Philip; Visser, Pieter Jelle

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Autoantibodies in patients with Alzheime

✍ Tania Colasanti; Cristiana Barbati; Giuseppe Rosano; Walter Malorni; Elena Orton 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 201 KB

Secondary endpoint and responder analyse

✍ Alderton, Claire; Zvartau-Hind, Marina; Ritchie, Sally; Saunders, Ann; Craft, Su 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

An immunohistochemical study of the sero

✍ Katsuyoshi Mizukami; Masanori Ishikawa; Hiroyasu Akatsu; Eric E. Abrahamson; Mil 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 461 KB

Safety and efficacy of tarenflurbil in s

✍ Gordon K. Wilcock; Sandra E. Black; Alfred H. Balch; David A. Amato; Andrew P. B 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 121 KB

Corrigendum to “Autoantibodies in patien

✍ Tania Colasanti; Cristiana Barbati; Giuseppe Rosano; Walter Malorni; Elena Orton 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 93 KB

O3-04-01: Safety and efficacy of tarenfl

✍ Robert C. Green; Lon S. Schneider; Suzanne B. Hendrix; Kenton H. Zavitz; Edward 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 55 KB